Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA

10/20/2021 | 06:38pm EST

Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine. The Johnson & Johnson booster shot will be the same formulation and dosage as the primary shot. The EUA follows a unanimous recommendation from the FDA'sVaccines and Related Biological Products Advisory Committee (VRBPAC) based on data provided by the Company, including efficacy, safety and immunogenicity data from its clinical trials and real-world evidence data. When administered as a primary or booster dose, following initial vaccination with the Company's COVID-19 single-shot vaccine, it provided protection against symptomatic disease and was generally well-tolerated, highlighting the favorable benefit-risk profile of a booster dose in light of the ongoing pandemic. A single booster dose of the Johnson & Johnson COVID-19 vaccine may also be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The eligible population(s) and dosing interval for the heterologous booster dose are the same as those authorized for a booster dose of the vaccine used for primary vaccination. The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) will provide a potential recommendation on October 21. In the U.S., there is sufficient supply to support boosting to those who have received the Johnson & Johnson COVID-19 vaccine. More than 15.2 million doses of the Company's COVID-19 vaccine have been administered as primary vaccinations in the U.S.


ę S&P Capital IQ 2021
All news about JOHNSON & JOHNSON
12:03pFDA Places Clinical Hold on Phase 3 Study for Ocugen COVID-19 Vaccine Covaxin
MT
11/25Johnson & Johnson COVID-19 Vaccine Fully Approved by Health Canada to Prevent COVID-19 ..
AQ
11/25CORONAVIRUS : Tanzania Broadens Choice for COVID - 19 Vaccines The government has so far a..
AQ
11/24Canada Health Allows Import of Johnson & Johnson's COVID-19 Vaccines Made by US Contrac..
MT
11/24Janssen COVID-19 vaccine plant in Baltimore gets Health Canada OK
AQ
11/24Johnson & Johnson, Pfizer Asked by South Africa to Delay COVID-19 Vaccine Deliveries Du..
MT
11/23JOHNSON & JOHNSON : European Commission Approves BYANNLI« (6-monthly Paliperidone Palmitat..
PU
11/23Almost 100 Million Doses of Johnson & Johnson COVID-19 Vaccine to be Donated to Lower I..
AQ
11/23J&J's Janssen Gets Europe OK for Twice-Yearly Schizophrenia Treatment
DJ
11/23CORONAVIRUS : The United States Donates Additional 840,000 Johnson & Johnson Vaccines to M..
AQ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 251 M - -
Net income 2021 22 542 M - -
Net Debt 2021 493 M - -
P/E ratio 2021 19,2x
Yield 2021 2,62%
Capitalization 419 B 419 B -
EV / Sales 2021 4,45x
EV / Sales 2022 4,14x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 159,20 $
Average target price 184,65 $
Spread / Average Target 16,0%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON1.82%421 847
ROCHE HOLDING AG17.17%334 769
PFIZER, INC.38.25%285 639
NOVO NORDISK A/S68.76%247 704
ELI LILLY AND COMPANY55.18%237 527
ABBVIE INC.10.74%209 777